CLR II C 7 The requirement of sufficiency of disclosure in the biotechnology field

7.1. Clarity and completeness of disclosure

7.2. Level of disclosure required for medical use – plausibility

7.3. Level of disclosure required for antibodies

7.4. Factors contributing to a finding of undue burden

7.5. Requirements relating to nucleotide and amino acid sequences

7.6. Deposit of living material

Source: http://www.epo.org/law-practice/legal-texts/html/caselaw/2019/e/clr_ii_c_7.htm

Date retrieved: 17 May 2021

9 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

Case Law Book

X CLR TOC OF CONTENTS

Case Law Book: II Conditions to be met by an Application

X CLR II C Sufficiency of disclosure

X CLR II C 1 Introduction

X CLR II C 7.1 Clarity and completeness of disclosure

X CLR II C 7.2 Level of disclosure required for medical use – plausibility

X CLR II C 7.3 Level of disclosure required for antibodies

X CLR II C 7.4 Factors contributing to a finding of undue burden

X CLR II C 7.5 Requirements relating to nucleotide and amino acid sequences

X CLR II C 7.6 Deposit of living material